Skip to Main Content
Recruiting

ANHL1931: Nivolumab and Chemoimmunotherapy for Lymphoma

About this study

Immunotherapy helps the body’s immune system find and kill cancer cells. When immunotherapy is combined with chemotherapy, this is called chemoimmunotherapy. This type of treatment can improve the ability to kill cancer cells.

Primary mediastinal B-cell lymphoma (PMBCL) is a type of non-Hodgkin lymphoma that is often treated with chemoimmunotherapy using a medicine called rituximab and chemotherapy.

Nivolumab (Opdivo™) is another kind of immunotherapy that helps the body’s own immune cells fight cancer. This clinical trial will study the effects of using the drug nivolumab to treat patients with PMBCL. This study will randomly divide patients (children, teens, and adults) into treatment groups, based on the combination of chemoimmunotherapy medicines they receive:

After 6 cycles of treatment (21 days each cycle), patients will have imaging tests and may or may not have a biopsy and radiation therapy.

Patients in this study will provide samples of blood, bone marrow, and spinal fluid from a lumbar puncture. This will help us find substances in the blood (biomarkers) that may show how well the treatment is working, Patients will also have imaging studies. The study will last about 4–6 months.

Eligibility overview

  • Primary mediastinal B-cell lymphoma (PMBCL)
  • 2 years and older
     

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemoimmunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Study goal:

To study the effects of nivolumab with chemoimmunotherapy versus chemoimmunotherapy alone in people with primary mediastinal B-cell lymphoma.

Diagnosis:

Primary Mediastinal B-cell Lymphoma

Age:

2 years and older

Clinical trials categories:

Childhood Cancer Non-Hodgkin Lymphoma

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more